A new doctoral training centre will train PhD students to design and build small molecules that can disrupt harmful protein-protein and lipid-protein interactions inside cells. These interactions are the molecular handshakes that control much of what happens in our bodies—when they go wrong, they can drive disease. The pharmaceutical industry has long struggled to interfere with them because the contact surfaces are large and flat, unlike the neat pockets where most existing drugs bind. This centre aims to bridge that gap by training researchers who combine the quantitative rigour of the physical sciences with the biological understanding needed to tackle these problems. If successful, the centre will produce a generation of scientists who can develop entirely new classes of drugs. That could eventually change how we treat diseases where protein interactions are central—cancer, inflammation, and neurodegenerative conditions among them. The work is fundamentally about building human capability: the students themselves are both the tool developers and the bridge that will carry these approaches from academia into the pharmaceutical industry.
View original technical description
The DTC's research will focus on the understanding of protein-protein and lipid-protein interaction.Quantitative measurement and modelling, of these macromolecular interactions, and the synthesis of new molecules with the ability to disrupt them will open up entirely novel avenues to attack diseases and ultimately be of clinical benefit.The Chemical Biology DTC is designed to exploit the UK's strong position in genomics by providing a bridge into new molecular post-genomic tools and technologies developed by DTC PhD researchers who work at the physical sciences/life sciences interface. The students are both the means by which the tools and technology are developed and the bridge that brings the quantitative perspectives of physical sciences to important biological problems. The need for such researchers has been highlighted by RCUK (http://w,Avw.rcuk.ac.uk/aboutreuk/executivegroup/egmeetings/feb07/070221report.htm) and thepharmaceutical sector (e.g. http://pubs.acs.org/cen/employment/84/8416chemicalbiology.html).Our particular focus on protein-protein and lipid-protein interactions has been chosen following consultation with senior research strategists from the pharmaceutical sector, who recognise that learning how to interfere with these interactions would form the basis for new pharmaceutical approaches to disease. However, they also recognise that such approaches will need to grow within academia and will require multidisciplinary researchers to carry these ideas with them and into industry. Their support of this proposal is a reflection of these longer term intentions.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know